Trilaciclib hydrochloride

• CAT Number: I013078
• CAS Number: 1977495-97-8
• Molecular Formula: C₂₄H₃₂Cl₂N₈O
• Molecular Weight: 519.47
• Purity: ≥95%
• Target: CDK
• Solubility: DMSO
• IUPAC Name: 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one;dihydrochloride
• InChI: InChI=1S/C24H30N8O.2ClH/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23;;/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29);2*1H
• InChIKey: BRCYOXKEDFAUSA-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6.Cl.Cl

Trilaciclib hydrochloride（Cat No.:I013078） is a novel, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), primarily developed to preserve bone marrow function during chemotherapy. By blocking CDK4/6 activity, trilaciclib induces a temporary cell cycle arrest in hematopoietic progenitor cells, reducing the incidence of chemotherapy-induced myelosuppression. This mechanism allows for improved recovery of blood cell counts, enhancing patient tolerance to cancer treatment. Trilaciclib has been investigated in various clinical trials, demonstrating efficacy in improving hematological parameters and overall patient outcomes, making it a significant advancement in supportive cancer care.

Reference

[1]. Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.